EUCTR2004-002627-40-IT进行中（未招募）不适用
Efficacy, safety, and tolerability of ezetimibe in coadministration with simvastin in the therapy of adolescent with heterozygous familial hypercholesterolemia
SCHERING-PLOUGH0 个研究点开始时间: 2005年11月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia - Pediatric HeFH StudyAdolescent (age >=10 and <=17 years) subjects with Heterozygous Familial Hypercholesterolemia (HeFH).MedDRA version: 7.0 Level: LLT Classification code 10057099EUCTR2004-002627-40-ESSchering-Plough Research Institute248
进行中（未招募）
不适用
Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia - Pediatric HeFH StudyAdolescent (age >=10 and <=17 years) subjects with Heterozygous Familial Hypercholesterolemia (HeFH).MedDRA version: 7.0Level: LLTClassification code 10057099EUCTR2004-002627-40-ATSchering-Plough Research Institute210
进行中（未招募）
不适用
Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia - Pediatric HeFH StudyEUCTR2004-002627-40-DESchering-Plough Research Institute on behalf of MSP Singapore Company, LLC210
进行中（未招募）
1 期
Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia - Pediatric HeFH StudyEUCTR2004-002627-40-FISchering-Plough Research Institute248
已完成
不适用
Assessment of efficacy and safety of ezetimibe in patients with dyslipidemia complicated insulin resistance.Dyslipidemia complicated insulin resistanceJPRN-UMIN000005775The Department of Diabetes, Endocrinology and Metabolism, Tokyo Medical University Hospital47